arrow
E

Elizabeth R. Plimack

Fox Chase Cancer Center
H指数:79
被引数:4.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Feasibility and Characterization of Immune-related Pathologic Response Criteria in Renal Cell Carcinoma

肾细胞癌中免疫相关病理反应标准的可行性与表征

2026-09-110
PRE
LONG-TERM FOLLOW-UP RESULTS OF AMVAC ARM OF ECOG-ACRIN EA8141: A PROSPECTIVE PHASE II TRIAL OF NEOADJUVANT SYSTEMIC CHEMOTHERAPY FOLLOWED BY EXTIRPATIVE SURGERY FOR PATIENTS WITH HIGH-GRADE UPPER TRACT UROTHELIAL CARCINOMA

ECOG-ACRIN EA8141试验中AMVC组的长期随访结果:一项针对高危上尿路尿路上皮癌患者的新辅助全身化疗后行根治性手术的二期前瞻性临床试验

2026-05-010
PRE
Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma
2025-11-010
PRE
Exploring Health-Related quality of life across the disease spectrum in renal cell carcinoma: a conceptual domain analysis

探索肾细胞癌疾病谱中健康相关生命质量的领域分析

2025-10-010
OA
Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma

三级淋巴结构的存在和耗竭性组织驻留T细胞决定了肾细胞癌对PD-1阻断的临床反应

2025-10-010
OAAI
Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank

开发生物标志物和风险分层方法:国际肾癌研讨会北美2024年思辨研讨会的共识声明

2025-09-010
PRE
Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial

转移性激素敏感性前列腺癌患者按PSA nadir划分的十年生存率:ECOG-ACRIN 3805(CHAARTED)试验的长期生存分析

2025-08-230
PREAI
Development of a Health-related Quality of Life Questionnaire for Patients with Metastatic or Localized Renal Cell Carcinoma

为转移性或局限性肾细胞癌患者开发健康相关生活质量问卷

2025-08-190
PRE
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial

帕博利珠单抗联合阿昔替尼对比舒尼替尼治疗晚期透明细胞肾细胞癌:KEYNOTE-426 III期试验的5年生存率和生物标志物分析

2025-08-010
OA
Genetic Drivers of Quality of Life in Prostate Cancer: An Evaluation of Genetic Polymorphisms and Patient-reported Outcomes in the E3805 CHAARTED trial

前列腺癌生命质量的遗传驱动因素:对E3805 CHAARTED试验中遗传多态性和患者报告结局的评估

2025-04-160
PRE
Nivolumab plus ipilimumab versus sunitinib for fi rst-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial

Nivolumab联合ipilimumab与舒尼替尼用于晚期肾细胞癌的一线治疗: CheckMate 214 III期试验的疗效和安全性的8年随访结果

2024-11-010
OAAI
Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial
2024-10-011
PRE
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study

Epacadostat联合pembrolizumab与安慰剂联合pembrolizumab治疗晚期尿路上皮癌: 随机III期ECHO-303/KEYNOTE-698研究的结果

2024-07-253
OAAI
Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma

肺免疫预后指数 (LIPI) 作为转移性肾细胞癌预后生物标志物的验证

2024-06-013
PRE
Bladder Cancer, Version 3.2024 Featured Updates to the NCCN Guidelines
2024-05-0113
OA
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)

nivolumab和savage nivolumab/ipilimumab治疗晚期透明细胞肾细胞癌的II期研究的无治疗生存结果 (HCRN GU16-260-Cohort A)

2024-04-112
OAAI
Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort

Beztifan治疗晚期实体瘤的I期LITESPARK-001研究: 在透明细胞肾细胞癌队列中延长41个月的随访

2024-01-017
PRE
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study[Eur Urol 84(5) (2023) 449-454]
2023-12-010
OA